Vunakizumab bests placebo in radiographic axial spondyloarthritis symptom improvement

Vunakizumab, a novel interleukin 17a monoclonal antibody, is superior to placebo in radiographic axial spondyloarthritis symptom improvement, according to data published in JAMA Network Open.“Nonsteroidal anti-inflammatory drugs (NSAIDs) are the recommended first-line pharmacologic treatment for [radiographic axial SpA (r-axSpA)],” Jian Zhu, MD, of the Chinese People’s